Yes, Ozempic is approved by the FDA. It received its initial approval in December 2017 as a treatment for type 2 diabetes in adults, and it has since gained additional approved uses. However, Ozempic is not FDA-approved for weight loss, despite its widespread use for that purpose.
What Ozempic Is Approved to Treat
Ozempic (semaglutide) is a once-weekly injectable medication with two FDA-approved indications. The first, granted in 2017, is as an add-on to diet and exercise to improve blood sugar control in adults with type 2 diabetes. The second, approved in January 2020, is to reduce the risk of major cardiovascular events like heart attack, stroke, or cardiovascular death in adults who have both type 2 diabetes and established heart disease.
More recently, the FDA-approved label has also been updated to reflect benefits for kidney health in adults with type 2 diabetes and chronic kidney disease. In every case, the approved use ties back to type 2 diabetes. If you don’t have type 2 diabetes, Ozempic has no FDA-approved indication for you.
Ozempic Is Not Approved for Weight Loss
This is the distinction that trips most people up. Ozempic and Wegovy contain the same active ingredient, semaglutide, but they are approved for different purposes. Wegovy is the version FDA-approved for weight management in adults and children 12 and older. It’s also approved for reducing cardiovascular risk in adults with obesity or overweight and heart disease, and for treating a specific form of liver disease called metabolic dysfunction-associated steatohepatitis (MASH).
Doctors can legally prescribe Ozempic off-label for weight loss, and many do. But “off-label” means the FDA has not reviewed or approved the drug specifically for that use at that dose. Wegovy also goes up to a higher maximum dose of 2.4 mg per week compared to Ozempic’s maximum of 2 mg, which is one reason research suggests Wegovy may be more effective for weight loss specifically.
How Ozempic Dosing Works
The FDA-approved dosing schedule for Ozempic starts low and gradually increases. You begin at 0.25 mg once a week for four weeks. That starting dose is purely to let your body adjust and isn’t meant to control blood sugar on its own. After four weeks, the dose increases to 0.5 mg weekly. If blood sugar control still isn’t adequate after at least another four weeks, your doctor may increase the dose to 1 mg weekly. The original maximum recommended dose was 1 mg, though the label has since been updated to allow up to 2 mg weekly.
Both Ozempic and Wegovy are now available as daily pills in addition to the injectable pen form. Ozempic uses a multi-use injection pen, meaning the same pen is used for multiple doses, while Wegovy uses single-use pens.
The Boxed Warning on the Label
Ozempic carries the FDA’s most serious type of warning, a boxed warning, related to thyroid tumors. In animal studies, semaglutide caused thyroid C-cell tumors. It’s unknown whether this risk applies to humans, but as a precaution, Ozempic is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or a condition called Multiple Endocrine Neoplasia syndrome type 2. If you notice a lump in your neck, difficulty swallowing, trouble breathing, or persistent hoarseness while taking Ozempic, those are symptoms worth getting checked immediately.
Compounded and Counterfeit Versions
The surge in demand for semaglutide led to widespread shortages over the past few years, which in turn fueled a market for compounded versions of the drug. Compounded semaglutide is mixed by specialty pharmacies rather than manufactured by Novo Nordisk, and it is not FDA-approved. That means the FDA has not reviewed these versions for safety, effectiveness, or quality.
As of early 2025, semaglutide no longer appears on the FDA’s official drug shortage list. With supply stabilizing, the FDA has clarified that compounders generally cannot produce drugs that are “essentially copies” of commercially available products. A compounded version qualifies as an essential copy if it contains the same active ingredient in the same or similar strength and is given by the same route as the brand-name drug. Compounded semaglutide is only appropriate when a patient’s medical needs genuinely cannot be met by an FDA-approved product.
The FDA has also flagged counterfeit Ozempic pens circulating in the U.S. These fakes may contain the wrong ingredients, incorrect doses, no active ingredient at all, or potentially harmful substances. The agency has received reports of adverse events possibly linked to compounded semaglutide prescribed at doses beyond what the FDA-approved label recommends.
What This Means in Practice
If you have type 2 diabetes, Ozempic is a fully FDA-approved treatment option with strong clinical evidence behind it. If your goal is weight loss and you don’t have type 2 diabetes, the FDA-approved product is Wegovy, not Ozempic, even though the active ingredient is identical. Your doctor may still prescribe Ozempic off-label for weight management, but it’s worth understanding the regulatory difference, especially when it comes to insurance coverage. Many insurers will only cover a drug for its FDA-approved indication, which can make Ozempic significantly more expensive when prescribed for weight loss alone.